Informa (INF) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
29 Oct, 2026Growth platform and outlook
Structural tailwinds span face-to-face B2B events and specialist knowledge, supported by trusted content, first-party data, AI and digitisation.
Platform characteristics include 5%+ underlying revenue growth, 8m+ B2B audiences, 30m+ first-party data records and 14k+ specialist talent across 40 countries.
H1 2026 underlying revenue growth was 6.8% and underlying adjusted operating profit growth was 6.9%, excluding non-recurring data contracts; B2B Live Events and Academic Markets performed strongly.
H1 reported revenue was £2,064m vs £2,036m; adjusted operating profit was £548m vs £579m; adjusted diluted EPS was 26.6p vs 29.8p.
2026 guidance reaffirmed: 6%± underlying revenue growth, including 7%+ for Live B2B Events and 4% for Academic Markets, plus double-digit underlying adjusted diluted EPS growth; interim dividend rose 6.9% to 7.48p and total buybacks set at £350m.
Pharma portfolio and reach
The pharma portfolio spans 36 years and reaches 323,000+ annual event attendees, 12,700+ exhibiting companies, 499,800+ professionals in its network and 153,900+ social media followers.
CPHI evolved from a pharma ingredients event to cover the supply chain from research through finished dosage, packaging and delivery; CPHI China and India also include PMEC machinery events.
Pharmapack serves packaging and drug delivery, with established European events and a Singapore launch; the portfolio includes events and specialist conferences across the Americas, Europe, Asia and the Middle East.
Recent initiatives include paid ticket models for CPHI Barcelona, CPHI & PMEC India and Pharmapack Europe, paid add-ons and upgrades, and four new zones at CPHI Milan.
CPHI Milan and future growth
CPHI Milan is positioned as a global meeting place for the pharma supply chain, with 60,000+ visitors, 2,900+ exhibitors, participants from 166+ countries and 300 expert speakers.
Four new zones covered AI & Tech, Cold Chain & Logistics, Contamination Control and Labelling; the event also included a co-located Sustainability Summit.
Planned growth levers include Lead Insights, optimised pass types, matchmaking, digital products and new event formats.
Latest events from Informa
- 9M revenue grew 6.5%; double-digit adjusted EPS growth guidance was reaffirmed.INF
Q3 2026 TU - Resilient subscriptions and cost actions anchor a £1.7bn FY21 transition-year baseline.INF
H2 2020 - Strong 2019 cash generation met COVID-19 disruption with ~£450m of events rescheduled.INF
H2 2019 - Revenue, cash and earnings grew as exhibitions and U.S. scale reshaped the portfolio.INF
H2 2016 - Underlying growth reached 3.7% as UBM integration advanced and synergies set up 2019.INF
H2 2018 - Strong cash generation and rising dividends funded a measured growth and portfolio reset.INF
H2 2014 - Record 26.4% operating margin, strong cash generation and lower debt marked FY2011.INF
H2 2011 - Revenue rose 30.7%, underlying growth accelerated, and 2018 growth target topped 3.5%.INF
H2 2017 - 10.1% five-month growth, a £0.5bn buyback and a Q4 2024 TechTarget target.INF
AGM 2024 & Trading update